Guiyang Xintian Pharmaceutical Co Ltd (002873) - Total Assets
Based on the latest financial reports, Guiyang Xintian Pharmaceutical Co Ltd (002873) holds total assets worth CN¥2.09 Billion CNY (≈ $306.09 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guiyang Xintian Pharmaceutical Co Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Guiyang Xintian Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 002873 stock market capitalisation for the company's overall valuation and market capitalisation.
Guiyang Xintian Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Guiyang Xintian Pharmaceutical Co Ltd's total assets of CN¥2.09 Billion consist of 30.7% current assets and 69.3% non-current assets. Review Guiyang Xintian Pharmaceutical Co Ltd total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.2% |
| Accounts Receivable | CN¥268.40 Million | 12.7% |
| Inventory | CN¥172.11 Million | 8.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥201.05 Million | 9.5% |
| Goodwill | CN¥6.19 Million | 0.3% |
Asset Composition Trend (2012–2025)
This chart illustrates how Guiyang Xintian Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Guiyang Xintian Pharmaceutical Co Ltd (002873) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guiyang Xintian Pharmaceutical Co Ltd's current assets represent 30.7% of total assets in 2025, a decrease from 61.6% in 2012.
- Cash Position: Cash and equivalents constituted 8.2% of total assets in 2025, down from 12.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 25.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 12.7% of total assets.
Guiyang Xintian Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Guiyang Xintian Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
USA | $511.25 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Savara Inc
NASDAQ:SVRA
|
USA | $192.14 Million |
Guiyang Xintian Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.34 | 2.16 | 1.50 |
| Quick Ratio | 0.99 | 1.68 | 1.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥156.90 Million | CN¥315.89 Million | CN¥239.53 Million |
Guiyang Xintian Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guiyang Xintian Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.61 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 8.7% |
| Total Assets | CN¥2.12 Billion |
| Market Capitalization | $286.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guiyang Xintian Pharmaceutical Co Ltd's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Guiyang Xintian Pharmaceutical Co Ltd's assets grew by 8.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Guiyang Xintian Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual total assets of Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.12 Billion ≈ $310.38 Million |
+8.75% |
| 2024-12-31 | CN¥1.95 Billion ≈ $285.42 Million |
+2.02% |
| 2023-12-31 | CN¥1.91 Billion ≈ $279.76 Million |
+3.69% |
| 2022-12-31 | CN¥1.84 Billion ≈ $269.81 Million |
+20.95% |
| 2021-12-31 | CN¥1.52 Billion ≈ $223.07 Million |
-0.75% |
| 2020-12-31 | CN¥1.54 Billion ≈ $224.76 Million |
+41.74% |
| 2019-12-31 | CN¥1.08 Billion ≈ $158.57 Million |
+10.09% |
| 2018-12-31 | CN¥984.31 Million ≈ $144.04 Million |
+14.94% |
| 2017-12-31 | CN¥856.40 Million ≈ $125.32 Million |
+55.84% |
| 2016-12-31 | CN¥549.54 Million ≈ $80.41 Million |
+10.05% |
| 2015-12-31 | CN¥499.36 Million ≈ $73.07 Million |
+6.76% |
| 2014-12-31 | CN¥467.76 Million ≈ $68.45 Million |
+23.18% |
| 2013-12-31 | CN¥379.74 Million ≈ $55.57 Million |
+12.74% |
| 2012-12-31 | CN¥336.84 Million ≈ $49.29 Million |
-- |
About Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of new traditional Chinese medicines in China. The company offers products in various dosage forms, including hard capsules, oral solutions, granules, gels, tablets, syrups, tinctures, lotions, medicated wines, and elixirs. Its products are used for the treatment of … Read more